| European Federation of Internal Medicine

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News

Type: News Feed

Human medicines European public assessment report (EPAR): Casgevy, exagamglogene autotemcel, Date of authorisation: 09/02/2024, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 19 February 2026 - 16:15

Human medicines European public assessment report (EPAR): Casgevy, exagamglogene autotemcel, Date of authorisation: 09/02/2024, Revision: 6, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Casgevy, exagamglogene autotemcel, Date of authorisation: 09/02/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Dovprela (previously Pretomanid FGK), pretomanid, Date of authorisation: 31/07/2020, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 19 February 2026 - 16:00

Human medicines European public assessment report (EPAR): Dovprela (previously Pretomanid FGK), pretomanid, Date of authorisation: 31/07/2020, Revision: 12, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Dovprela (previously Pretomanid FGK), pretomanid, Date of authorisation: 31/07/2020, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 31, Status: Authorised

Submitted by Anonymous (not verified) on 19 February 2026 - 15:30

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 31, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Waskyra, etuvetidigene autotemcel, Date of authorisation: 09/01/2026, Status: Authorised

Submitted by Anonymous (not verified) on 19 February 2026 - 15:29

Human medicines European public assessment report (EPAR): Waskyra, etuvetidigene autotemcel, Date of authorisation: 09/01/2026, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Waskyra, etuvetidigene autotemcel, Date of authorisation: 09/01/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 27, Status: Authorised

Submitted by Anonymous (not verified) on 19 February 2026 - 15:10

Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 27, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Klisyri, tirbanibulin, Date of authorisation: 16/07/2021, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 19 February 2026 - 15:00

Human medicines European public assessment report (EPAR): Klisyri, tirbanibulin, Date of authorisation: 16/07/2021, Revision: 6, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Klisyri, tirbanibulin, Date of authorisation: 16/07/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 22, Status: Authorised

Submitted by Anonymous (not verified) on 19 February 2026 - 14:10

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 22, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Uptravi, selexipag, Date of authorisation: 12/05/2016, Revision: 20, Status: Authorised

Submitted by Anonymous (not verified) on 19 February 2026 - 13:20

Human medicines European public assessment report (EPAR): Uptravi, selexipag, Date of authorisation: 12/05/2016, Revision: 20, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Uptravi, selexipag, Date of authorisation: 12/05/2016, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Kigabeq, vigabatrin, Date of authorisation: 20/09/2018, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 19 February 2026 - 13:15

Human medicines European public assessment report (EPAR): Kigabeq, vigabatrin, Date of authorisation: 20/09/2018, Revision: 8, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Kigabeq, vigabatrin, Date of authorisation: 20/09/2018, Revision: 8, Status: Authorised

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Human medicines European public assessment report (EPAR): Casgevy, exagamglogene autotemcel, Date of authorisation: 09/02/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Dovprela (previously Pretomanid FGK), pretomanid, Date of authorisation: 31/07/2020, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Waskyra, etuvetidigene autotemcel, Date of authorisation: 09/01/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Klisyri, tirbanibulin, Date of authorisation: 16/07/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Uptravi, selexipag, Date of authorisation: 12/05/2016, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Kigabeq, vigabatrin, Date of authorisation: 20/09/2018, Revision: 8, Status: Authorised

Newsletters

Latest Newsletters

You are here

Newsletters

Latest Newsletters